Coherus Oncology, Inc.
CHRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 12.8% | 34.9% | -86% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 67.8% | 66.9% | 65.1% | 37.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -356.3% | -405.4% | -581.7% | -81.9% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -307.1% | 2,903.9% | -744.4% | -93.6% |
| EPS Diluted | -0.31 | -0.36 | -0.49 | -0.44 |
| % Growth | 13.9% | 26.5% | -11.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |